Analysis of the Sweat Response According to the Pathology in Neurologic Patients
Sudoscan
1 other identifier
observational
450
0 countries
N/A
Brief Summary
Cardiovascular autonomic neuropathy (CAN) has been shown to be an important risk factor for cardiac diseases, particularly in diabetes. CAN may be investigated by a battery of laboratory cardiovascular autonomic reflex tests(initially described by Ewing). First screening for CAN (as proposed in diabetic patients) can be performed by assessing heart rate (HR) response to deep breathing, blood pressure (BP) and HR response to a 5 minutes stand test
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2015
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2017
CompletedFirst Submitted
Initial submission to the registry
August 17, 2018
CompletedFirst Posted
Study publicly available on registry
August 21, 2018
CompletedAugust 21, 2018
August 1, 2018
2 years
August 17, 2018
August 20, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Sweating autonomic test
Evaluate the performance of the laboratory battery of CV tests and of sweating dysfunction to differentiate MSA-P from PD
baseline
Study Arms (2)
MSA-P
Patients with multiple systeme atrophy (MSA) with predominant parkinsonism (MSA-P) had evaluation of cardiovascular function and sweating function
PD patients
Parkinson's disease (PD) patients had evaluation of cardiovascular function and sweating function
Interventions
Sweating dysfunction by Sudoscan
Eligibility Criteria
Patients referred to the autonomic laboratory of the neurology department at Toulouse University Hospital
You may qualify if:
- Patients with MSA-P or PD
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anne Pavy-Le Traon, MD
University Hospital, Toulouse
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 17, 2018
First Posted
August 21, 2018
Study Start
March 1, 2015
Primary Completion
March 1, 2017
Study Completion
March 1, 2017
Last Updated
August 21, 2018
Record last verified: 2018-08
Data Sharing
- IPD Sharing
- Will not share